Skip to content
NASDAQ · ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS · SMALL CAP

electroCore, Inc. ECOR

9 fiscal years on record · USD · FY2025 reported · SEC filings only
$32.0M
▲ 27.2% YoY
$-14.0M
$-8.3M

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

In brief

What this company does

Our business generates revenues from the sale of prescription medical devices and non-prescription wellness products in the United States and select overseas markets. As of February 1, 2026, we employed 83 full-time employees. None of our employees are represented by a labor union or covered by a collective bargaining agreement. On May 1, 2025 (the “NURO Closing Date”), the Company completed its previously announced acquisition of NeuroMetrix pursuant to the terms of the Agreement and Plan of Merger dated as of December 17, 2024 (the “Merger Agreement”) by and among the Company, NURO, and Nexus Merger Sub Inc., a Delaware corporation and a wholly owned subsidiary of the Company (“Merger Sub”).

Written from the business description in electroCore, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 19 March 2026. Every sentence was checked against that document before publication.

Growth

USD 32.0M
Revenue, FY2025 · full 9-year series below
Revenue $M Net income $M
FY2025 · Revenue 32.0 · Net income -14.0
15M30M-20M-40M
2017202020232025
Compound annual growth
+55.1%
+55.7%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +55.7% a year over the five years to FY2025.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

−44 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -41.1% · Net -43.6%
-2000%-4000%
201720212025
ROE
FY2024 · ROE -158.6%
-50%-100%-150%
201720212025
Three returns, three denominators.
Return on equityNot applicable: equity was zero or negative in this period, so return on equity has no meaning.

Return on equity has no reading this year — return on capital employed, just below, still does: -141%.

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -8.3
-20M-40M
201720212025

Total assetsUSD 18.7M
EquityUSD -1.7M
CashUSD 7.0M
Gross debtUSD 6.6M
Net debtUSD -428,000.00
Current ratio1.38×

Equity was zero or negative — liabilities equaled or exceeded assets. No ratio is shown.

The 9-year record

9 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
ECOR, 9-year financial record
Metric 202520242023202220212020201920182017
Revenue $B0.00.00.00.00.00.00.00.00.0
Operating income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.1−0.0
EBITDA $B◌−0.0−0.0−0.0−0.0−0.0−0.0−0.1−0.0
Income tax $B0.0−0.0−0.0−0.0−0.0−0.00.00.0◌
Net income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.1−0.0
Free cash flow $B−0.0◌−0.0◌◌◌−0.0−0.0−0.0
EPS, diluted $−1.65−1.59−3.42−4.69−4.36−0.60−1.54−1.19◌
Dividend / sh $◌◌◌◌◌◌◌◌◌
Payout % — not applicable: no dividend—————————
ROE %—−158.6−153.6−82.5−57.7−99.5−100.5——
Shares out B0.010.010.010.000.070.050.030.030.00

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 1 failure in 44 reconciliationsAUDITED

Reconciled in 8 of the 9 fiscal years we could check. 20 checks were skipped: the balance sheet is not tagged before 2017. 11 checks were skipped: EPS is not tagged before 2018. 10 checks were skipped: revenue is not tagged before 2017.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency1 failure
ActivityElectromedical & Electrotherapeutic Apparatus
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2017

Share this section

Download image